Literature DB >> 8447257

Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged < or = 50 years) and women (< or = 60 years) with coronary artery disease.

P O Kwiterovich1, J Coresh, P S Bachorik.   

Abstract

The prevalence and clinical characteristics of hyperapobetalipoproteinemia (hyperapoB) and other phenotypes of dyslipoproteinemia were examined in 99 men (aged < or = 50 years) and 104 women (< or = 60 years) undergoing elective diagnostic coronary arteriography. HyperapoB was the most common phenotype (34%) associated with premature coronary artery disease (CAD). Only 20.2% of patients with CAD had a normal lipoprotein phenotype. The significant odds ratios for CAD were as follows: hypertriglyceridemic hyperapoB 17.45 (p < 0.0001), type IV 6.54 (p = 0.0001), type IIa 4.73 (p = 0.008), normotriglyceridemic hyperapoB 2.54 (p = 0.03) and type IIb 8.73 (p = 0.05). The strong association of hypertriglyceridemic hyperapoB with CAD reflected the multiplicative effect of increased low-density lipoprotein apolipoprotein B and endogenous hypertriglyceridemia, and was independent of the effects of age, sex, diabetes mellitus, systemic hypertension, body mass index and cigarette smoking. The ratio of apolipoprotein B to A-1 was better than those of low-density to high-density lipoprotein cholesterol and total to high-density lipoprotein cholesterol at discriminating dyslipidemic phenotypes from normal. Obesity was increased approximately 1.5 to two-fold in the hypertriglyceridemic phenotypes, diabetes was more prevalent in hypertriglyceridemic hyperapoB (6.8-fold; p < 0.001) and type IV (4.4-fold; p = 0.02), and hypertension was increased 1.5- to twofold in most dyslipidemic groups. The data indicate that hyperapoB and endogenous hypertriglyceridemia both contribute to the risk of premature CAD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8447257     DOI: 10.1016/0002-9149(93)91002-y

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Variations in plasma lipid concentration during examination stress.

Authors:  B S McCann; G A Benjamin; C W Wilkinson; J Carter; B M Retzlaff; J Russo; R H Knopp
Journal:  Int J Behav Med       Date:  1996

2.  Reference distributions for apolipoproteins AI and B and B/AI ratios: comparison of a large cohort to the world's literature.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Thomas B Ledue; Santica Marcovina; Olga Navolotskaia
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

Review 3.  Pathophysiology of dyslipidaemia in the metabolic syndrome.

Authors:  G D Kolovou; K K Anagnostopoulou; D V Cokkinos
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

4.  Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis.

Authors:  Haitham M Ahmed; Michael Miller; Khurram Nasir; John W McEvoy; David Herrington; Roger S Blumenthal; Michael J Blaha
Journal:  Am J Epidemiol       Date:  2016-04-18       Impact factor: 4.897

5.  Relationship between smoking and dyslipidemia in western Chinese elderly males.

Authors:  X J Tan; G P Jiao; Y J Ren; X R Gao; Y Ding; X R Wang; H Xu
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

6.  Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.

Authors:  Vasilios G Athyros; Konstantinos Tziomalos; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

7.  The abnormal lipid profile in obesity and coronary heart disease (CHD) in Pakistani subjects.

Authors:  Saleem Ullah Shahid; Sumbal Sarwar
Journal:  Lipids Health Dis       Date:  2020-04-14       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.